The added value of H2 antagonists in premedication regimens during paclitaxel treatment
暂无分享，去创建一个
A. Jager | R. Mathijssen | I. Boere | R. V. van Leeuwen | P. van den Bemt | T. M. Bosch | R. Malmberg | L. van Doorn | E. Oomen-de Hoop | J. Cox | P. M. van den Bemt | E. Oomen‐de Hoop